Evidence map›Paper›PMID 40165248›Full record

ArticleBMC medicine2025

Enhancing anti-CD3 mAb-mediated diabetes remission in autoimmune diabetes through regulation of dynamin-related protein 1(Drp1)-mediated mitochondrial dynamics in exhausted CD8

Ruiling Zhao, Zhangyao Su, Junjie Gu, Hang Zhao, Lingling Bian, Yin Jiang, Yun Cai, Tao Yang, Yong Gu, Xinyu Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruiling Zhao *Department of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.
Zhangyao Su *Department of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.
Junjie GuDepartment of Radiation Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China.
Hang ZhaoDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.
Lingling BianDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.
Yin JiangDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.
Yun CaiDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.
Tao YangDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.
Yong GuDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China. yong.gu@njmu.edu.cn.
Xinyu XuDepartment of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China. drxinyuxu@njmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntigen-specific immunotherapy shows potential for inducing long-term immune tolerance in type 1 diabetes (T1D), yet its clinical application is hampered by uncertainty regarding dominant epitopes. Conversely, non-antigen-specific treatments such as anti-CD3 monoclonal antibodies (mAbs) present a more straightforward approach but struggle to maintain tolerance after treatment. Addressing these issues is critical for advancing T1D therapies.

methodsThe phenotypic and metabolic properties of two subsets of exhausted CD8

resultsOur study reveals the diversity of two distinct exhausted CD8

conclusionsOur results point to a new immunotherapeutic approach that targets exhausted CD8

Indexed as

Antibodies, MonoclonalCD3 ComplexCD8-Positive T-LymphocytesDiabetes Mellitus, Type 1DynaminsMitochondrial DynamicsAnimalsFemaleHEK293 CellsHumansImmunotherapyMiceMice, Inbred NODReceptors, Antigen, T-CellAntibodies, MonoclonalCD3 ComplexDNM1L protein, humanDynaminsReceptors, Antigen, T-CellAutoimmunityCD3 mAbExhausted T cellImmune toleranceImmunotherapy

Identifiers

PMID40165248
PMCPMC11959779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.